Several studies suggest that overexpression of AXL may result in resistance to both targeted therapies and conventional chemotherapy in different models, such as lung cancer [41], breast cancer [101], esophageal carcinoma [49], gastrointestinal stromal tumors [102], and AML [103]. The gene discussed is AXL; the disease is lung carcinoma.